J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M300482-JLR200 on March 1, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M300482-JLR200v1
45/6/1084    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Bu, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Bu, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 45, 1084-1091, June 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Degradation of the LDL receptor class 2 mutants is mediated by a proteasome-dependent pathway

Yonghe Li1,*, Wenyan Lu*, Alan L. Schwartz*,{dagger} and Guojun Bu*,§

* Departments of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO 63110
{dagger} Molecular Biology and Pharmacology, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO 63110
§ Cell Biology and Physiology, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO 63110

1 To whom correspondence should be addressed. e-mail: LI_YO{at}kids.wustl.edu

Familial hypercholesterolemia is a genetic disorder that results from various gene mutations, primarily within the LDL receptor (LDLR). Approximately 50% of the LDLR mutations are defined as class 2 mutations, with the mutant proteins partially or entirely retained in the endoplasmic reticulum. To determine the degradation pathway of the LDLR class 2 mutants, we examined the effects of inhibition of several potential pathways on the levels of the wild-type LDLR and its four representative class 2 mutants (S156L, C176Y, E207K, and C646Y) stably expressed in Chinese hamster ovary (CHO) cells. We found that proteasome inhibitors MG132 and lactacystin blocked the degradation of the LDLR mutants, but not that of the wild-type LDLR. Treatment of CHO cells with these proteasome inhibitors led to a significant accumulation of the mutants at steady state. Furthermore, cell surface levels of the LDLR mutants were significantly increased upon inhibition of the proteasome degradation pathway. In contrast to the proteasome inhibitors, inhibitors of trypsin-like proteases, chymotrypsin-like proteases, and lysosomal pathway inhibitors did not affect the levels of the LDLR mutants.

Taken together, these data demonstrate that the proteasome is the principal degradation pathway for LDLR class 2 mutants.

Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; CHO, Chinese hamster ovary; ER, endoplasmic reticulum; FH, familial hypercholesterolemia; LDLR, LDL receptor; LRP, LDL receptor-related protein; RAP, receptor-associated protein; SREBP, sterol-regulatory element binding protein

Supplementary key words familial hypercholesterolemia • mutation • degradation


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
E. R. Eden, X.-M. Sun, D. D. Patel, and A. K. Soutar
Adaptor protein Disabled-2 modulates low density lipoprotein receptor synthesis in fibroblasts from patients with autosomal recessive hypercholesterolaemia
Hum. Mol. Genet., November 15, 2007; 16(22): 2751 - 2759.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Sorensen, T. Ranheim, K. S. Bakken, T. P. Leren, and M. A. Kulseth
Retention of Mutant Low Density Lipoprotein Receptor in Endoplasmic Reticulum (ER) Leads to ER Stress
J. Biol. Chem., January 6, 2006; 281(1): 468 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Castro-Fernandez, G. Maya-Nunez, and P. M. Conn
Beyond the Signal Sequence: Protein Routing in Health and Disease
Endocr. Rev., June 1, 2005; 26(4): 479 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. N. Maxwell, E. A. Fisher, and J. L. Breslow
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
PNAS, February 8, 2005; 102(6): 2069 - 2074.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.